Bimatoprost - SpyGlass Pharma
Latest Information Update: 27 Nov 2024
Price :
$50 *
At a glance
- Originator SpyGlass Pharma
- Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glaucoma; Ocular hypertension
Most Recent Events
- 27 Nov 2024 SpyGlass plans to work with the US Food and Drug Administration (FDA) to advance Bimatoprost into phase III clinical development
- 19 Nov 2024 SpyGlass Pharma completes enrolment in the phase I/II Tigris trial for Glaucoma in USA (Ophthalmic)
- 18 Nov 2024 SpyGlass Pharma plans a phase III trial for Glaucoma